Depression

Ohio

95 Depression Trials near Ohio

Power is an online platform that helps thousands of Depression patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
This trial is testing a type of therapy called Mindfulness-Based Cognitive Therapy, provided over the phone, through video calls, or as part of regular care with added support. It aims to help people with migraines and depressive symptoms by teaching them to focus on the present moment and understand their thought patterns better. Mindfulness-Based Cognitive Therapy (MBCT) was developed to prevent relapse in recurrent depression by combining cognitive behavioral therapy and meditative techniques.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

144 Participants Needed

The goal of this clinical trial is to test the feasibility of the Individualized Positive Psychosocial Interaction (IPPI) with 108 nursing home residents living with dementia and distress or depressive symptoms. The main questions it aims to answer are: •is it feasible to deliver the IPPI and track impact through data collected in the electronic medical records. Care partners will engage eligible residents in 2 brief preference-based IPPIs per week over the course of 6 months.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

135 Participants Needed

A phase II, randomized, open-label, two-arm clinical trial evaluating the safety and efficacy of pramipexole extended release (ER) versus escitalopram for the treatment of major depressive disorder (MDD) and comorbid MDD with mild neurocognitive disorder (MND) in persons with HIV (PWH). Participants will be assessed comprehensively and briefly at intercurrent visits to monitor for toxicity, response to therapy, and to assess for dose changes. An optional sub-study to evaluate treatment impact on the cerebrospinal fluid (CSF) profile will be conducted in a subset of 36 participants.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 2

186 Participants Needed

This trial will test if a special type of talk therapy can help teenagers who have had depression before by stopping them from overthinking negative thoughts. The goal is to see if this can prevent them from getting depressed again. This therapy was developed to specifically target depressive rumination and has shown effectiveness in reducing depressive symptoms and relapse rates.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:14 - 17

183 Participants Needed

Evaluate the efficacy of accelerated theta burst stimulation (aTBS) in reducing depressive symptoms in autism spectrum disorder (ASD)

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:13 - 26

24 Participants Needed

This research seeks to improve the Midlife Black Women's Stress Reduction and Wellness Intervention (B-SWELL), a program designed to lower heart disease risk in midlife Black women. The B-SWELL leverages stress reduction to facilitate the adoption and adherence to healthier lifestyle behaviors. This research study will use choice to increase engagement and minimize the effect of social determinants of health on research participation among midlife Black women. A comparative clinical trial will be conducted. Midlife Black women (ages 45-64) who reside in the Greater Cincinnati area will be recruited for participation. Women are eligible if they self-identify as Black/ African American, are between the ages of 45-64, and are willing to commit to the requirements of the study (e.g., attend 8 weekly sessions and 4 phone interviews). Participants will be randomly placed (like the flip of a coin) into either the B-SWELL or WE group. Both the B-SWELL and WE groups are 8-week programs that focus on healthy lifestyle behaviors and heart disease awareness. Women will have the choice to participate in person or virtually. Survey phone interviews will be conducted at baseline, 8-, 12-, and 16-weeks. Data collected will provide information about adherence, healthy lifestyle behaviors, and cardiovascular health. Heart health will be measured using the American Heart Association's Life's Essential 8 metric. Outcome measures include heart disease awareness, Life's Essential 8 score, stress, self-efficacy, depressive symptoms, and symptoms.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:45 - 64
Sex:Female

64 Participants Needed

The goal of this randomized controlled trial is to determine the feasibility, acceptability, and preliminary effects of a web-based parent training (Parenting Wisely) augmented with facilitated parent groups (referred to as PWRT). PWRT is designed to prepare parents for the reintegration of their adolescents in the home after intensive psychiatric residential treatment. Researchers will compare PWRT to treatment as usual to determine whether PWRT effects target mechanisms (i.e., family function, social support, parental self-efficacy, parenting practices) and adolescent outcomes (i.e., internalizing and externalizing behaviors, placement restrictiveness).

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:11+

60 Participants Needed

The goal of this study is to refine and test a strategy for engaging Veterans with symptoms of depression, anxiety, and/or PTSD (Post Traumatic Stress Disorder) as volunteers to help English language learners (ELLs) improve their speaking skills via structured conversations using videoconferencing.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

80 Participants Needed

The researchers hope to learn whether an electronic safety plan (ESP) and a supportive text messaging program are feasible and acceptable to adult patients with recent suicidal thoughts or behavior after emergency department (ED) discharge. From this study, the researchers also hope to learn how to best carry out the ESP and text messaging program to improve outcomes for patients after ED discharge.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:18 - 65

120 Participants Needed

Pediatric traumatic injury (PTI) is a public health priority, with more than 125,000 children experiencing injuries that require hospitalization each year. These children, and their caregivers, are affected in many ways that may affect quality of life, emotional and behavioral health, physical recovery, family roles and routines, and academic functioning; yet US trauma centers do not adequately address these outcomes and a scalable national model of care for these families is needed. This proposal builds on prior research from the investigative team to test a technology-assisted, stepped care behavioral health intervention for children (\<12 years) and their caregivers after PTI, CAARE (Caregivers' Aid to Accelerate Recovery after pediatric Emergencies), via a hybrid type I effectiveness-implementation trial with 348 families randomly assigned to CAARE (n=174) vs. guideline-adherent enhanced usual care (EUC) (n=174).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

348 Participants Needed

Large-scale, effective, low-cost, and evidence-based programs that can nimbly translate new research discoveries into prevention and care for psychosocial-based problems are urgently needed since the vast majority of people who need evidence-based care do not receive it. The purpose of this randomized control trial is to investigate the feasibility and efficacy of a Mood Lifters group template specifically for undergraduate students. Mood Lifters is an effective peer-led program that improves or maintains mental health. It seeks to help people enhance pleasure, engagement, and meaning in their lives while minimizing depression, fear, loneliness, and other negative feelings via a proprietary peer-based program that offers weekly meetings and other flexible support options. One obstacle to providing mental health care in the US is that it is costly to provide one-on-one therapy by a licensed professional. This is particularly true in large group settings with limited resources (counseling centers) and a large need for mental health care, like universities.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

150 Participants Needed

This trial tests if text message reminders combined with self-checks can help people with high blood pressure and Bipolar Disorder take their medicine more regularly. The goal is to see if this method works better than just doing self-checks alone.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:21 - 80

175 Participants Needed

Homelessness severely affects health and well-being and is particularly negative for youth. Between 70-95% of youth experiencing homelessness (YEH) report problem substance use and 66-89% have a mental health disorder. Youth appear to be at greater risk for living on the streets or being homeless than adults and are more vulnerable to long term consequences of homelessness. Multiple social determinants of health (SDOH) are uniquely associated with homelessness, driving substance use and adverse mental health consequences. However, limited research has identified pragmatic interventions that have a long-term ameliorating impact on the complex, multi-symptomatic issues among these youth. This study overcomes prior gaps in research through testing a multi-component comprehensive prevention intervention targeting SDOH that may affect biopsychosocial health indicators and longer-term health outcomes. In partnership with a drop-in center for YEH, youth between the ages of 14 to 24 years, will be engaged and randomly assigned to conditions using a dismantling design so that essential intervention components can be efficiently identified. In particular, youth (N = 300) will be randomly assigned to a) Motivational Interviewing/Community Reinforcement Approach + Services as Usual (MI/CRA + SAU, n = 80), b) Strengths-Based Outreach and Advocacy + Services As Usual (SBOA + SAU, n = 80), c) MI/CRA + SBOA + SAU (n = 80) or d) SAU (n=60) through the drop-in center. In order to assess the longer-term prevention effects on substance use, mental health and other outcomes, all youth will be assessed at baseline and at 3, 6, 12, 18 and 24-months post-baseline. The primary goal of this study is to establish the impact of a comprehensive intervention embedded within a system that serves YEH, a community drop-in center, on youth's opioid misuse and disorder, other substance misuse and disorders, mental health diagnoses, and other targeted outcomes. This study will offer unique information on the physiological and psychological stress pathways underlying change for specific subgroups of youth along with cost estimates to inform future implementation efforts in drop-in centers around the country.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:14 - 24

300 Participants Needed

Babies with single ventricle congenital heart disease (SVCHD) are often diagnosed during pregnancy. While prenatal diagnosis has important clinical benefits, it is often stressful and overwhelming for parents, and many express a need for psychological support. HeartGPS is a psychological intervention for parents who receive their baby's diagnosis of SVCHD during pregnancy. It includes 8 sessions with a psychologist, coupled with tailored educational resources, and a personalized care plan. The intervention focuses on fostering parent psychological adjustment and wellbeing, and supporting parents to bond with their baby in ways that feel right for them. Through this study, the investigators will learn if HeartGPS is useful and effective for parents and their babies when it is offered in addition to usual fetal cardiac care. The investigators will examine the effects of the HeartGPS intervention on parental anxiety, depression, and traumatic stress; fetal and infant brain development; parent-infant bonding; and infant neurobehavioral and neurodevelopmental outcomes. The investigators will also explore mechanisms associated with stress biology during pregnancy, infant brain development and neurodevelopmental outcomes, and parent and infant intervention effects.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

104 Participants Needed

This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
Stay on current meds
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:7+

200000 Participants Needed

ALA-3000 for Depression

North Canton, Ohio
This is a randomized, double-blind, placebo-controlled, multiple-dose study of ALA-3000 designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy in subjects with treatment-resistant depression (TRD).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65

44 Participants Needed

This trial is testing if aticaprant can help adults with major depressive disorder who haven't responded well to current antidepressants. The medication works by targeting brain chemicals to improve mood and pleasure.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Age:18 - 64

350 Participants Needed

This trial tests a new medication in people with major depression who haven't improved with at least two other treatments. The drug works by changing brain chemicals to improve mood quickly. It has been approved for adults with difficult-to-treat depression and has been tested in various forms.

Trial Details

Trial Status:Recruiting
Age:18 - 65

90 Participants Needed

This trial is testing a new medication called COMP360 to help people with severe depression that hasn't improved with other treatments. The study involves adults aged 18 and older. Researchers want to see if a single dose of COMP360 can reduce depression symptoms when given with psychological support.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

255 Participants Needed

This study is being done to better understand how the study team can treat pain for people with cirrhosis and depression. Enrolled participants on this feasibility study will be randomized to Transcutaneous Electrical Acustimulation (TEA) or sham TEA.

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

30 Participants Needed

Why Other Patients Applied

"I have dealt with depression my entire adult life. I have been on multiple different meds, went through 10 weeks of TMS treatments (didn't work for me personally), done fairly extensive counseling. I’ve kind of lost hope that anything will ever help me to feel better. But I learned about new meds in clinical trials and I'm ready to try."

YP
Depression PatientAge: 60

"My long history of depression has been met with a long list of trial and error drugs. My current medication (generic Pristiq) has been prescribed for two decades (though I tried several other medications during my last serious episode several years ago. When the episode passed I returned to generic Pristiq. I am interested in a clinical trial because I wonder if I can do something different to more effectively avoid a serious depressive episode and lift the general malaise I often feel."

DD
Depression PatientAge: 62

"Dealt with treatment-resistant depression for pretty much my entire life. I would be eternally grateful for something that actually worked for once. I'd just like to feel normal. "

CM
Depression PatientAge: 55

"I’ve had depression for many years and been on a LOT of different medications. They work for awhile and then they just stop working. It’s very frustrating. I am very open to trying something new and different. Just looking to fight this, head on."

ZX
Depression PatientAge: 55

"I’m ready to move on with my life. I did a poor job bouncing back from COVID (dealing with a disability). I'd already had a PTSD diagnosis after my spouse died. These past few years have been tough and I'd like to feel like I'm alive again. I need help getting out of this phase."

FY
Depression PatientAge: 60
The investigators propose to examine the effects of CSC services delivered via TH (CSC-TH) versus the standard clinic-based CSC model (CSC-SD) on engagement and outcomes in a 12-month, randomized trial.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:16 - 35

180 Participants Needed

This study aims to investigate the feasibility and effectiveness of a cognitive behavioral coping skills program, Treatment and Education Approach for Childhood-onset Lupus (TEACH), for youth with cSLE when integrated into medical care. This TEACH program aims to teach participants skills in order to cope with fatigue, pain, and depressive symptoms--symptoms that commonly affect adolescents and young adults with lupus.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:12 - 22

196 Participants Needed

Behavioral health problems, such as depression and anxiety, are common yet often are not identified by emergency department doctors and nurses. These mental health conditions can be due to medical issues or can worsen medical problems. One way investigators hope to do a better job of learning about mental health is by training Artificial Intelligence (AI) software to detect anxiety and depression by analyzing facial expression and tone of voice. Participants are invited to participate in a study which may help improve emergency department care. An audio and video recording of the participant's responses to some simple, non-psychological questions will be analyzed by a computer to determine whether investigators can assess mood and anxiety by analyzing speech and visual patterns. The audio and video will not be listened to nor watched by study personnel, only analyzed by a computer. The investigator's hope is that it will help others in the future by aiding in the assessment of psychological state. This study is being conducted at CMC ED only.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

30 Participants Needed

Up to a quarter of the families with preterm infants have unmet social needs, such as housing or job insecurity, which represent adverse social determinants of health (SDOH). Preterm infants are especially vulnerable to the social conditions they grow up in, with sustained impacts on function across multiple organ systems. The goal of this study is to translate an established model of SDOH screening and referral from the outpatient setting to the NICU, thereby maximizing the potential to offset the effects of adverse SDOH on vulnerable mother-preterm infant dyads.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Sex:Female

882 Participants Needed

This trial is testing COMP360, a new treatment for adults who have not responded to other depression treatments. Participants will receive one of three doses of COMP360 along with psychological support. The goal is to see if this combination can help improve their depression symptoms.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

568 Participants Needed

Aticaprant for Depression

Ann Arbor, Michigan
This trial is testing aticaprant to see if it can help adults with major depressive disorder and anhedonia who haven't responded well to other antidepressants. Aticaprant works by blocking certain receptors in the brain to potentially improve depressive symptoms.
Stay on current meds
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:22 - 74

710 Participants Needed

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000 in subjects with bipolar I disorder.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 2

200 Participants Needed

The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to \[\>=\] 6 and less than \[\<\] 12 years of age), adolescents (\>=12 and \<18 years of age), and adults (\>=18 years of age) with Tourette's Syndrome (TS).
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:6+

150 Participants Needed

ROSE-010 for Obesity

Cincinnati, Ohio
The primary objective of this study is to assess the efficacy of ROSE-010 on food intake in female subjects with overweight and obesity. The secondary objectives of this study are the following: * To assess the efficacy of ROSE-010 on hunger; * To assess the efficacy of ROSE-010 on satiety; * To assess the efficacy of ROSE-010 on prospective consumption; * To assess the efficacy of ROSE-010 on desire to eat; * To assess the efficacy of ROSE-010 on palatability; * To characterize the pharmacokinetics (PK) of ROSE-010 following subcutaneous (SC) administration on Day 1 and Day 7; and * To evaluate safety and tolerability of SC administrations of ROSE-010 to overweight and obese subjects.

Trial Details

Trial Status:Not Yet Recruiting
Age:18 - 65
Sex:Female

40 Participants Needed

Propofol for Anesthesia

Ann Arbor, Michigan
The researchers expect to gain a deeper understanding of mental function during different levels of anesthesia, and to evaluate if the use of ultrasonic brain stimulation accelerates return to consciousness. Propofol is FDA approved for use in patients undergoing an anesthetic for medical treatment but is not approved for use in healthy volunteers.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 40

28 Participants Needed

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Depression clinical trials in Ohio pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Depression clinical trials in Ohio work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Depression trials in Ohio 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Ohio for Depression is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Ohio several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Depression medical study in Ohio?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Depression clinical trials in Ohio?

Most recently, we added Ketamine for Chronic Lower Back Pain and Depression, CYB003 for Depression and ESP + Text Support for Suicide Prevention to the Power online platform.

What do the "Power Preferred" and "SuperSite" badges mean?

We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.

Which clinics have received Power Preferred and SuperSite awards recruiting for Depression trials in Ohio?

The Depression clinics in Ohio currently recognized as SuperSites are: The Ohio State University Wexner Medical Center (OSUWMC) - OSU Harding Hospital in Columbus, Ohio

What are the current treatment options for depression?

Doctors use a stepped-care approach. First, most people try evidence-based talk therapy (such as CBT or interpersonal therapy), an antidepressant medicine (SSRIs are typical), or both, while also improving sleep, exercise and diet. If symptoms persist, the next “step” is to add or switch treatments—e.g., combining two medicines, adding lithium or an antipsychotic, or using brain-stimulation methods like transcranial magnetic stimulation or, for severe cases, electroconvulsive therapy; newer options such as esketamine nasal spray are reserved for treatment-resistant depression. Working with a clinician to review progress every few weeks and adjust the plan is key to finding the right mix.

When is depression considered severe?

Doctors call a depressive episode “severe” when almost all of the nine core symptoms are present at high intensity, the person’s daily life has largely shut down (can’t work, study, or manage self-care), or there are high-risk features like active suicidal thoughts, a recent attempt, or hallucinations/false beliefs. On common checklists this usually means a PHQ-9 score of 20 or higher, and it signals the need for urgent, comprehensive care—often a combination of medication, psychotherapy, and sometimes hospitalization. If you or someone you know reaches this point, treat it as an emergency and contact a mental-health professional or call/text 988 (USA) or your local crisis line right away.

Is it possible to never be depressed again?

Some people have a single episode of depression and stay well, but the risk of another episode is higher if you stop treatment too soon, have had several episodes before, or still have mild symptoms. You can greatly lower that risk by continuing the treatment that got you better for at least 6–12 months, learning relapse-prevention skills in CBT or mindfulness therapy, keeping regular sleep, exercise, and social routines, and checking in early with a professional if warning signs return. In short, there is no iron-clad guarantee you’ll never be depressed again, but staying on maintenance care and a healthy lifestyle makes long-term wellness much more likely.

What are the top 3 symptoms of depression?

Doctors look first for three core signs: 1) a low or hopeless mood that hangs around most of the day, nearly every day; 2) a marked loss of interest or pleasure in things you used to enjoy (called anhedonia); and 3) big changes in body energy—feeling drained, sleeping or eating far more or less than usual. If any of these have lasted two weeks or longer, it’s time to talk with a health professional, because other symptoms can pile on and treatment works best when started early.

Is depression a chemical imbalance?

No—depression can’t be pinned on one missing brain chemical. Research shows it arises from a mix of factors: how your brain circuits and several neurotransmitters work, your genes, long-term stress, and life circumstances all interact. Because causes differ from person to person, the most effective care is usually a combination of approaches—medication when needed, talking therapies, and lifestyle changes—worked out with your clinician.

How many people have untreatable depression?

Doctors call “untreatable” depression “treatment-resistant depression,” meaning the person has not improved after trying at least two suitable antidepressants. Large studies show this applies to roughly one-quarter to one-third of people with major depression—about 2–3 % of adults overall, or roughly 5–8 million U.S. adults in any given year. Importantly, many still respond to other options such as medication combinations, ketamine/esketamine, transcranial magnetic stimulation, or electroconvulsive therapy.

How to get out of deep depression?

Think of recovery as two tracks that run side-by-side. Track 1: get professional help right away—if you ever feel unsafe call 988 (or your local hotline), and with a clinician discuss proven treatments such as CBT, antidepressant medicine, and, when needed, newer options like ketamine, transcranial magnetic stimulation or electroconvulsive therapy. Track 2: reinforce the medical plan daily with mood-boosting basics—consistent exercise, regular sleep, balanced meals, limited alcohol or drugs, and time with supportive people—because these habits make the treatments work better and give you small, sustainable lifts while you heal.

Why is depression so hard to treat?

Depression is hard to treat because it isn’t a single disease—each person’s symptoms arise from a unique blend of brain chemistry, genetics, stress, medical issues, and life circumstances—so one-size-fits-all therapies rarely work. Without a blood test to guide choices, clinicians must try treatments sequentially, and roughly one-third of people need several steps or a combination of medication, talk therapy, lifestyle changes, or newer options like ketamine or magnetic stimulation before they feel well. The encouraging news is that persistence with a systematic plan and attention to sleep, exercise, and co-existing conditions allows most patients to eventually reach full recovery.

What are unhealthy coping mechanisms for depression?

Unhealthy coping means doing things that give quick relief but actually deepen depression—common examples include using alcohol or other drugs, overeating or not eating, oversleeping or endless screen-scrolling to avoid feelings, cutting or other self-harm, harsh self-talk and rumination, and withdrawing from friends or lashing out at them. These behaviors worsen mood, relationships, and safety; if you notice yourself relying on them, reach out to a trusted person or mental-health professional (or call your local crisis line) and ask about safer skills such as problem-solving steps, scheduled activity, or therapy.

Is it OK to have clinical depression?

Yes—having clinical depression isn’t a personal failing; it’s a common medical illness, and recognising it is the first step toward feeling better. What isn’t OK is to face it alone, because untreated depression can worsen and raise the risk of other problems, whereas most people improve with timely care such as talk therapy, medication, or a combination. If symptoms last more than two weeks or include thoughts of self-harm, book a visit with a primary-care doctor or mental-health professional and, in crisis, call 988 (U.S.) or your local emergency number—effective help and recovery are the norm when treatment is started.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security